Pathology

Bipartisan Legislation Makes Patient Safety a National Priority

Retrieved on: 
Monday, March 11, 2024

This landmark bipartisan legislation, announced during Patient Safety Awareness Week, is a critical step to improve safety for patients and healthcare providers by adopting patient safety solutions.

Key Points: 
  • This landmark bipartisan legislation, announced during Patient Safety Awareness Week, is a critical step to improve safety for patients and healthcare providers by adopting patient safety solutions.
  • The National Patient Safety Board Act would create a National Patient Safety Board (NPSB), a data-driven, nonpunitive, collaborative, independent research and development team housed within the Department of Health and Human Services to address safety in health care.
  • The establishment of a National Patient Safety Board would enable a collaborative, evidence-based and scalable solution to optimize patient safety across our country’s healthcare system,” said Peter WT Pisters, MD, president of The University of Texas MD Anderson Cancer Center.
  • “Patient safety is our number one priority for every decision we make as a health system.

UCLA and PreciseDx Announce New Collaboration to Advance AI-Enabled Predictions and Risk Mitigation for Triple-Negative Breast Cancer Recurrence

Retrieved on: 
Tuesday, April 2, 2024

NEW YORK, April 2, 2024 /PRNewswire/ -- PreciseDx®, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis, today announced a sponsored research collaboration with UCLA's Department of Pathology and Laboratory Medicine in Los Angeles to evaluate PreciseBreast's™ ability to accurately assess risk of recurrence for patients with triple-negative breast cancer (TNBC). TNBC constitutes only 10-20% of all breast cancer cases, yet continues to demand significant clinical interest due to its limited response to conventional treatments, the association with younger women, BRCA1/2 mutations, ethnic/racial disparities, and its highly aggressive characteristics. 

Key Points: 
  • Our collaboration with PreciseDx has the potential to greatly improve our approach to predicting and managing recurrence in TNBC patients, ultimately leading to enhanced outcomes."
  • Integrating advanced AI algorithms and comprehensive clinical data, the collaborative study aims to confirm PreciseBreast as a highly effective and reliable digital breast cancer assay.
  • This new assay will potentially enhance the early detection of TNBC recurrence and support personalized treatment strategies tailored to individual patient needs.
  • The collaborative study between UCLA and PreciseDx represents a significant step forward in digital pathology and oncology breast cancer research.

New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Retrieved on: 
Thursday, March 28, 2024

OSLO, Norway, March 28, 2024 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week.

Key Points: 
  • OSLO, Norway, March 28, 2024 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week.
  • This study aims to evaluate heterogeneity in characteristics of blue light cystoscopy (BLC®) for detection of malignant lesions among various races with non-muscle invasive bladder cancer (NMIBC).
  • The authors conclude that regardless of race, BLC increased the detection of bladder cancer when combined with WLC.
  • However, the difference was more pronounced in Asian patients: "Our study showed that regardless of race, BLC increases the detection of bladder cancer when combined with WLC.

New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Retrieved on: 
Thursday, March 28, 2024

OSLO, Norway, March 28, 2024 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week.

Key Points: 
  • OSLO, Norway, March 28, 2024 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week.
  • This study aims to evaluate heterogeneity in characteristics of blue light cystoscopy (BLC®) for detection of malignant lesions among various races with non-muscle invasive bladder cancer (NMIBC).
  • The authors conclude that regardless of race, BLC increased the detection of bladder cancer when combined with WLC.
  • However, the difference was more pronounced in Asian patients: "Our study showed that regardless of race, BLC increases the detection of bladder cancer when combined with WLC.

University of Medicine and Health Sciences Names Award-Winning Medical Educator and Physician Dr. Shivayogi Bhusnurmath as Dean of Basic Sciences

Retrieved on: 
Tuesday, March 26, 2024

NEW YORK, March 26, 2024 /PRNewswire-PRWeb/ -- The University of Medicine and Health Sciences, (UMHS), a small, mission-driven medical school with a commitment to student support and a legacy of successful residency placements in the United States and Canada, has named Dr. Shivayogi Bhusnurmath, an award-winning medical educator and pioneering physician, as its new Dean of Basic Sciences. Dr. Bhusnurmath will advance the university's focus on providing quality medical education, preparing future doctors to deliver compassionate care, and ensuring the continued growth and development of UMHS.

Key Points: 
  • Dr. Bhusnurmath will advance the university's focus on providing quality medical education, preparing future doctors to deliver compassionate care, and ensuring the continued growth and development of UMHS.
  • His approach resonates deeply with our mission of delivering personalized education and preparing our graduates to lead with compassion and distinction."
  • Dr. Bhusnurmath has spent four decades developing curriculum at leading medical schools and brings with him a wealth of medical knowledge, clinical experience, and academic leadership.
  • Trained in India at the prestigious Postgraduate Institute of Medical Education and Research, Chandigarh, Dr. Bhusnurmath obtained his Fellowship from the Royal College of Pathologists, London.

Retail Clinic Utilization Increased 202 Percent Nationally from 2021 to 2022, according to Seventh Annual FAIR Health Report

Retrieved on: 
Tuesday, March 26, 2024

NEW YORK, March 26, 2024 /PRNewswire/ -- Retail clinic utilization increased 202 percent nationally from 2021 to 2022, and emergency room (ER) utilization increased 138 percent.1 Retail clinics and ERs had the greatest increases in utilization among the places of service studied—which also included urgent care centers, telehealth and ambulatory surgery centers (ASCs)—in a new FAIR Health white paper containing the seventh annual edition of FH® Healthcare Indicators and FH® Medical Price Index. Like the previous editions, this year's edition of FH Healthcare Indicators and FH Medical Price Index is intended to provide perspective for all healthcare stakeholders in a rapidly changing healthcare environment.

Key Points: 
  • Focusing on alternative places of service and ERs, FH Healthcare Indicators evaluate changes in utilization, geographic and demographic factors, diagnoses, procedures and costs.
  • Among the other key findings:
    ASC utilization increased 88 percent nationally from 2021 to 2022; urgent care center utilization increased 43 percent and telehealth 8 percent in the same period.
  • Telehealth accounted for 3.9 percent of medical claim lines, urgent care centers 2.1 percent, ASCs 1.1 percent and retail clinics 0.2 percent.
  • The pathology and laboratory charge amount index increased four percent, while the surgery charge amount index increased three percent.

Yunkang Announces 2023 Annual Results, Revenue Reaches RMB892 Million

Retrieved on: 
Monday, March 25, 2024

HONG KONG, March 25, 2024 /PRNewswire/ -- Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2023 (the "Reporting Period"). In 2023, the Group continued to expand its business network and services across the country, the Group's revenue reached RMB891.5 million. The Group's routine testing business achieved a healthy and steady year-on-year growth of 26.9% during the Reporting Period. Due to enhanced operational and management capabilities and improved cost control, the overall gross profit margin remained stable at 36.5%. The Group further improved its operational and management capabilities and strengthened its cash flow management, resulting in a significant improvement in net cash generated from operating activities as compared with last year. As at December 31, 2023, the Group's cash and cash equivalents amounted to RMB1,244.1 million. The Board of Directors resolved to recommend the payment of a final dividend of HK$0.02 per share for the year ended December 31, 2023. 

Key Points: 
  • In 2023, the Group continued to expand its business network and services across the country, the Group's revenue reached RMB891.5 million.
  • As at December 31, 2023, the Group's cash and cash equivalents amounted to RMB1,244.1 million.
  • The Board of Directors resolved to recommend the payment of a final dividend of HK$0.02 per share for the year ended December 31, 2023.
  • During the Reporting Period, the Group's investment in R&D amounted to RMB55.3 million, which increased as a percentage of operating revenue to 6.2% for the year ended December 31, 2023.

Now Available! Gestalt Announces PathFlow's AI Algorithm Evaluator

Retrieved on: 
Friday, March 22, 2024

SPOKANE, Wash., March 22, 2024 /PRNewswire/ -- Gestalt Diagnostics, Inc., a leading provider of (AI)-driven digital pathology solutions, is proud to announce the launch of its leading-edge AI Algorithm Evaluator. This groundbreaking, patent-pending tool empowers pathologists, researchers, and healthcare professionals to assess and compare the performance of AI algorithms with unprecedented precision directly within our award-winning PathFlow® solution. This new feature will be demonstrated during the USCAP 2024 conference in Baltimore this week.

Key Points: 
  • SPOKANE, Wash., March 22, 2024 /PRNewswire/ -- Gestalt Diagnostics, Inc. , a leading provider of (AI)-driven digital pathology solutions, is proud to announce the launch of its leading-edge AI Algorithm Evaluator.
  • Key Features of PathFlow's AI Algorithm Evaluator:
    Side-by-Side Evaluation: The AI Algorithm Evaluator allows users to compare the results of similar algorithms simultaneously.
  • Whether it's accuracy, speed, or other relevant factors, the AI Algorithm Evaluator adapts to your needs.
  • The AI Algorithm Evaluator provides a digital audit trail, documenting the basis on which algorithms are selected.

Ibex Presents New Data from Multiple Studies Showcasing Accuracy of AI in Prostate, Breast and Gastric Cancer Diagnosis

Retrieved on: 
Thursday, March 21, 2024

BOSTON, March 21, 2024 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham and Women's Hospital, Champalimaud Foundation and Ohio State University (OSU). These studies, highlighting the value of Ibex's AI-powered cancer diagnostics solutions in both diagnostic quality and efficiency, will be presented next week at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting.

Key Points: 
  • Brigham and Women's Hospital and Champalimaud Foundation research shows high accuracy levels of Galen Breast in identifying microinvasive carcinoma of the breast.
  • Ohio State University Wexner Medical Center studies show high accuracy for Galen Breast and Galen Gastric in detecting and distinguishing between different types of cancer and in identifying multiple important pathologies.
  • In addition, researchers from OSU Wexner Medical Center will present studies validating Galen Breast's performance in detecting different types of breast cancer.
  • Ibex will be showcasing these findings at the USCAP Annual Meeting taking place in Baltimore, Maryland, between March 23 to 28, at booth number 755.

GLG to Provide Expert Insights for Sohn Idea Contest for Innovative Investments

Retrieved on: 
Wednesday, March 20, 2024

NEW YORK, March 20, 2024 /PRNewswire/ -- GLG, the world's insight network, will sponsor the Sohn Idea Contest of the 29th annual New York Sohn Investment Conference on April 3, 2024 at New York City's Lincoln Center, in partnership with CNBC. The contest is designed to identify the next big innovative, timely, and actionable investment idea, and the winner will work with GLG to enhance their presentation with top expert insights. The winner will then present on stage at the conference, which convenes top hedge fund and alternative investors to share market insights and raise funds in support of pediatric cancer research.

Key Points: 
  • The contest is designed to identify the next big innovative, timely, and actionable investment idea, and the winner will work with GLG to enhance their presentation with top expert insights.
  • GLG will help the winner of the Sohn Idea Contest advance their investment thesis with insights from leading experts around the world.
  • "We're proud to once again sponsor the Sohn Idea Contest to advance lifesaving cancer research while doing what we do best – fueling innovation with the power of expert insights."
  • In 2020 and 2021, The Sohn Conference Foundation provided funding for the university's development of a novel monoclonal antibody therapy for COVID-19.